Biomarker: M201-IgE Tilletia Tritici

Overview

M201-IgE measures serum allergen-specific immunoglobulin E (IgE) directed against an extract of Tilletia tritici and related smut or bunt fungi. These fungi produce airborne spores that may cause sensitization after inhalation, particularly in agricultural and grain-handling environments. A detectable result indicates immunologic sensitization, but it does not by itself establish symptomatic allergy, asthma, or hypersensitivity pneumonitis, and the IgE concentration does not predict disease severity. The test is clinically useful as an adjunct to exposure history and respiratory or allergic symptoms when evaluating possible mold-related disease.

Clinical Use Cases

Assessing possible IgE-mediated sensitization to Tilletia tritici or related smut fungi.
Supporting evaluation of work-related rhinitis, asthma, cough, or wheezing in farmers, grain handlers, and other individuals exposed to cereal dust or fungal spores.
Investigating suspected fungal triggers in patients with asthma or allergic respiratory symptoms.
Supplementing skin-prick testing when skin testing is unsuitable, unavailable, or affected by medications or extensive skin disease.
Supporting, but not independently establishing, evaluation of hypersensitivity pneumonitis or other occupational respiratory disorders.
Interpreting results alongside exposure history, symptom timing, pulmonary function testing, and other allergy or respiratory investigations.

Specimen Types

Venous blood, typically processed as serum.
Some allergen-specific IgE platforms may accept plasma, depending on the laboratory method and validated specimen requirements.

Measurement Methods

Solid-phase allergen-specific IgE immunoassay.
Fluorescence enzyme immunoassay, including ImmunoCAP-type methods.
Other validated immunoassays using Tilletia tritici or related smut-fungus extract.
Skin-prick testing with a relevant fungal extract may be used as a complementary, but separate, assessment.

Test Preparation and Influencing Factors

Fasting is generally not required for an allergen-specific IgE blood test.
Patients should report all medications and supplements to the clinician.
Antihistamines commonly affect skin-prick testing but generally do not prevent collection of a specific-IgE blood sample. Medication changes should only be made with clinical guidance.
Results should be interpreted with the timing, intensity, and setting of exposure to grain dust or airborne fungal spores.
Recent or ongoing exposure may be relevant when correlating the result with occupational symptoms.
A positive result indicates sensitization and may occur without clinical symptoms.
A negative result does not completely exclude allergy, particularly if the relevant allergen extract does not represent the patient’s sensitizing proteins.
Cross-reactivity with other basidiomycete molds may affect interpretation.
Assay cutoff values, reporting units, and classifications vary by platform and laboratory.
Total IgE, atopy, asthma, age, and other allergic or inflammatory conditions may influence the clinical interpretation of specific-IgE results.
Specific-IgE concentration should not be used alone to estimate the severity of a future allergic reaction.